Clinical trials: Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases, Relapsing Multiple Sclerosis
Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
The proposed randomized, open label, with treat as usual control group (standard treatment or any disease modifying drugs), crossover phase II study will be conducted in 40 patients (n=20 per group) with the relapsing forms of…
- Trial name
- NCT03183869
- Testing
- Fecal microbiota
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Chronic Migraine; Multiple Sclerosis; Motoneuron Disease
Feasibility and Effectiveness of a Mindfulness Program Delivered by Web to Patients During Hospitalization and Caregivers.
Hospitalization is often a traumatic event so stressful for the life of patients. Isolation, loneliness, worries about clinical examinations, results from examinations and final diagnosis, uncertainty about the future are the…
- Trial name
- KIMPO (NCT05623254)
- Testing
- no comparator - TAU (Treatment-as-usual)
- Where
- Italy
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Multiple Sclerosis
Views on Physical Activity Following a Relapse in People With Multiple Sclerosis
Multiple Sclerosis (MS) is the most common cause of neurological disability in young adults. Relapsing Remitting Multiple Sclerosis (RRMS) is the most frequent form of MS at the time of diagnosis characterised by relapses…
- Trial name
- NCT03736902
- Testing
- Qualitative semi structured interview
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- City, University of London
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
The aim of this study is to develop novel magnetic resonance imaging (MRI) protocols suitable for patients with multiple sclerosis using advanced MRI such as rotating frame relaxation imaging.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
- Trial name
- ROMUS (NCT02403570)
- Testing
- Brain MRI
- Where
- Finland
- Volunteers
- 21 people
- Sponsor
- Turku University Hospital
Multiple Sclerosis
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
The primary objective of the study is to determine physician reported persistence with the Avonex PEN at Month 12/End of Study as well as determining factors associated with persistence.
- Trial name
- PERSIST (NCT01405872)
- Testing
- AVONEX PEN
- Where
- 64 sites in Denmark, France and 8 more
- Volunteers
- 270 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT02753088
- Testing
- BCD-063, Copaxone-Teva
- Volunteers
- 158 people
- Sponsor
- Biocad
Multiple Sclerosis
Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis
This is a pilot feasibility study to examine the impact of providing a non-therapeutic resilience-based coaching telehealth program to the Support Partners (SP) of persons with MS (PwMS).
- Trial name
- NCT03555253
- Testing
- Resilience-Based Program for Support Partners of PwMS
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Healios Inc.
Multiple Sclerosis, Urinary Incontinence (UI)
URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS
This study aims to investigate the relationship between urinary incontinence severity and surface electromyography (EMG) findings in women with multiple sclerosis.
- Trial name
- MS-UI-PFM (NCT07489794)
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Multiple Sclerosis, Relapsing-Remitting
Photobiomodulation Therapy in Persons With Multiple Sclerosis
This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.
- Trial name
- NCT03691766
- Testing
- Photobiomodulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Marquette University
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Scelrosis
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
- Trial name
- ASCLEPIOS II (NCT02792231)
- Testing
- Ofatumumab subcutaneous injection, Teriflunomide capsule
- Where
- 178 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Novartis Pharmaceuticals
Fatigue, Multiple Sclerosis
Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)
Fatigue is a symptom present in 76 to 92% of people with multiple sclerosis (MS). Fatigue is usually described as an overwhelming sense of tiredness, lack of energy, and feeling of exhaustion which is different from sleepiness.
- Conditions
- Fatigue, Multiple Sclerosis, Sleep Apnea
- Trial name
- NCT01563900
- Testing
- Auto-titration CPAP
- Where
- United States
- Sponsor
- Northwestern University
Multiple Sclerosis, Relapsing-Remitting
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with relapsing forms of multiple sclerosis.
- Trial name
- NCT01435993
- Testing
- GSK1223249
- Where
- 2 sites in Italy, Norway
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Multiple sclerosis (MS) is an immune-mediated disease characterized primarily by inflammatory demyelinating lesions in the central nervous system (CNS), with the white matter being predominantly affected.
- Trial name
- NCT07353216
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Multiple Sclerosis, Peripheral Neuropathy
Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy
This study will evaluate the effects of mindfulness and concentration meditation on pain, fatigue, and physical functioning in patients with either multiple sclerosis or peripheral neuropathy.
- Trial name
- NCT00981643
- Testing
- Meditation instruction and practice
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Cleveland Clinic
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Multiple Sclerosis, Relapsing-Remitting
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
This study will examine the safety of Zenapax (daclizumab) in patients with multiple sclerosis (MS). MS is thought to be caused by an over-reactive immune response.
- Trial name
- NCT00071838
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01093326
- Testing
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 353 people
- Sponsor
- Actelion
Neuromyelitis Optica
Safety and Tolerability of Rituximab in Neuromyelitis Optica
The goal of this research study is to investigate whether Rituximab is safe to use in patients suffering from NMO, or who are at high risk for developing NMO.
- Trial name
- NCT00501748
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.